The future is today: Emerging drugs for the treatment of erectile dysfunction

Maarten Albersen, Alan W. Shindel, Kuwong B. Mwamukonda, Tom F. Lue

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Importance of the field: Erectile dysfunction (ED) is the most common male sexual dysfunction presented for treatment affecting between 10 and 20% of men. PDE type 5 inhibitors (PDE5I) now account for the largest segment of the ED market. While these drugs are highly efficacious for many men, a relatively large subset of ED patients who do not respond to PDE5I is increasingly recognized. Areas covered in this review: In this review, we discuss clinical and preclinical evidence supporting various emerging compounds that regulate penile erection both centrally (clavulanic acid, dopamine and melanocortin receptor agonists) and peripherally (novel PDE5I, soluble and particulate guanylil cyclase activators, rho-kinase inhibitors and maxi-K channel openers). What the reader will gain: The reader will gain a broad understanding of erectile (patho-)physiology and gain insights in the mechanisms of action, efficacy and adverse events of various compounds under development for the treatment of ED. Take home message: We expect emerging drugs to allow treatment protocols tailored to the specific needs of each individual patient, taking into consideration the efficacy of erectile performance enhancement and the potential for adverse events. This tailored approach may include combination of various emerging drugs to enhance efficacy in difficult-to-treat patients.

Original languageEnglish (US)
Pages (from-to)467-480
Number of pages14
JournalExpert Opinion on Emerging Drugs
Volume15
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Erectile Dysfunction
Phosphodiesterase 5 Inhibitors
Pharmaceutical Preparations
Melanocortin Receptors
Large-Conductance Calcium-Activated Potassium Channels
Penile Erection
rho-Associated Kinases
Clavulanic Acid
Dopamine Agonists
Therapeutics
Clinical Protocols

Keywords

  • Clavulanic acid
  • Dopamine
  • Guanylil cyclase
  • Maxi-K channel
  • Melanocortin receptor
  • Particulate
  • PDE5 inhibitor
  • Rho-kinase
  • Soluble

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The future is today : Emerging drugs for the treatment of erectile dysfunction. / Albersen, Maarten; Shindel, Alan W.; Mwamukonda, Kuwong B.; Lue, Tom F.

In: Expert Opinion on Emerging Drugs, Vol. 15, No. 3, 09.2010, p. 467-480.

Research output: Contribution to journalArticle

Albersen, Maarten ; Shindel, Alan W. ; Mwamukonda, Kuwong B. ; Lue, Tom F. / The future is today : Emerging drugs for the treatment of erectile dysfunction. In: Expert Opinion on Emerging Drugs. 2010 ; Vol. 15, No. 3. pp. 467-480.
@article{78e30b9d21dc4cc4ba605afc1575be66,
title = "The future is today: Emerging drugs for the treatment of erectile dysfunction",
abstract = "Importance of the field: Erectile dysfunction (ED) is the most common male sexual dysfunction presented for treatment affecting between 10 and 20{\%} of men. PDE type 5 inhibitors (PDE5I) now account for the largest segment of the ED market. While these drugs are highly efficacious for many men, a relatively large subset of ED patients who do not respond to PDE5I is increasingly recognized. Areas covered in this review: In this review, we discuss clinical and preclinical evidence supporting various emerging compounds that regulate penile erection both centrally (clavulanic acid, dopamine and melanocortin receptor agonists) and peripherally (novel PDE5I, soluble and particulate guanylil cyclase activators, rho-kinase inhibitors and maxi-K channel openers). What the reader will gain: The reader will gain a broad understanding of erectile (patho-)physiology and gain insights in the mechanisms of action, efficacy and adverse events of various compounds under development for the treatment of ED. Take home message: We expect emerging drugs to allow treatment protocols tailored to the specific needs of each individual patient, taking into consideration the efficacy of erectile performance enhancement and the potential for adverse events. This tailored approach may include combination of various emerging drugs to enhance efficacy in difficult-to-treat patients.",
keywords = "Clavulanic acid, Dopamine, Guanylil cyclase, Maxi-K channel, Melanocortin receptor, Particulate, PDE5 inhibitor, Rho-kinase, Soluble",
author = "Maarten Albersen and Shindel, {Alan W.} and Mwamukonda, {Kuwong B.} and Lue, {Tom F.}",
year = "2010",
month = "9",
doi = "10.1517/14728214.2010.480973",
language = "English (US)",
volume = "15",
pages = "467--480",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The future is today

T2 - Emerging drugs for the treatment of erectile dysfunction

AU - Albersen, Maarten

AU - Shindel, Alan W.

AU - Mwamukonda, Kuwong B.

AU - Lue, Tom F.

PY - 2010/9

Y1 - 2010/9

N2 - Importance of the field: Erectile dysfunction (ED) is the most common male sexual dysfunction presented for treatment affecting between 10 and 20% of men. PDE type 5 inhibitors (PDE5I) now account for the largest segment of the ED market. While these drugs are highly efficacious for many men, a relatively large subset of ED patients who do not respond to PDE5I is increasingly recognized. Areas covered in this review: In this review, we discuss clinical and preclinical evidence supporting various emerging compounds that regulate penile erection both centrally (clavulanic acid, dopamine and melanocortin receptor agonists) and peripherally (novel PDE5I, soluble and particulate guanylil cyclase activators, rho-kinase inhibitors and maxi-K channel openers). What the reader will gain: The reader will gain a broad understanding of erectile (patho-)physiology and gain insights in the mechanisms of action, efficacy and adverse events of various compounds under development for the treatment of ED. Take home message: We expect emerging drugs to allow treatment protocols tailored to the specific needs of each individual patient, taking into consideration the efficacy of erectile performance enhancement and the potential for adverse events. This tailored approach may include combination of various emerging drugs to enhance efficacy in difficult-to-treat patients.

AB - Importance of the field: Erectile dysfunction (ED) is the most common male sexual dysfunction presented for treatment affecting between 10 and 20% of men. PDE type 5 inhibitors (PDE5I) now account for the largest segment of the ED market. While these drugs are highly efficacious for many men, a relatively large subset of ED patients who do not respond to PDE5I is increasingly recognized. Areas covered in this review: In this review, we discuss clinical and preclinical evidence supporting various emerging compounds that regulate penile erection both centrally (clavulanic acid, dopamine and melanocortin receptor agonists) and peripherally (novel PDE5I, soluble and particulate guanylil cyclase activators, rho-kinase inhibitors and maxi-K channel openers). What the reader will gain: The reader will gain a broad understanding of erectile (patho-)physiology and gain insights in the mechanisms of action, efficacy and adverse events of various compounds under development for the treatment of ED. Take home message: We expect emerging drugs to allow treatment protocols tailored to the specific needs of each individual patient, taking into consideration the efficacy of erectile performance enhancement and the potential for adverse events. This tailored approach may include combination of various emerging drugs to enhance efficacy in difficult-to-treat patients.

KW - Clavulanic acid

KW - Dopamine

KW - Guanylil cyclase

KW - Maxi-K channel

KW - Melanocortin receptor

KW - Particulate

KW - PDE5 inhibitor

KW - Rho-kinase

KW - Soluble

UR - http://www.scopus.com/inward/record.url?scp=77955879920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955879920&partnerID=8YFLogxK

U2 - 10.1517/14728214.2010.480973

DO - 10.1517/14728214.2010.480973

M3 - Article

C2 - 20415601

AN - SCOPUS:77955879920

VL - 15

SP - 467

EP - 480

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -